



Colorectal Cancer and Melanoma

With the acquisition of Array BioPharma in 2019, Pfizer is well-positioned to establish a strong franchise in colorectal cancer (CRC), the third most common type of cancer in both men and women worldwide.

Looking forward, we are excited about the ongoing expansion of both our CRC and melanoma portfolios, including continuing to investigate biomarker-driven regimens that may be able to help more people in need.

Click below for more information on the role of biomarkers in metastatic melanoma and metastatic CRC:

